IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription

Growth Factors

Volumn 28, Issue 4, 2010, Pages 243-255

  Mireuta, Matei ^a   Darnel, Andrew ^a   Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

AKT; IGFBP 2; MRNA; MTOR; PI3K; Sp1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR SP1;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MORPHOLINES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; SOMATOMEDINS; SP1 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 77957780986     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977191003745472     Document Type: Article

References (46)

1. Baxter R. 1993. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 4:91-96.
2. Beck T, Hall MN. 1999. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402:689-692.
3. Blume-Jensen P, Hunter T 2001. Oncogenic kinase signalling. Nature 411:355-365.
4. Boisclair YR, Brown AL, Casola S, Rechler MM. 1993. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem 268:24892-24901.
5. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. 1998. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adreno-cortical tumors. J Clin Endocrinol Metab 83:1713-1720.
6. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H. 2005. Significant expression ofIGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58: 361-366.
7. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. 1999. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 274:30215-30221.
8. Chan TW, Pollak M, Huynh H. 2001. Inhibition ofinsulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res 7:2545-2554.
9. Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT, Fontana JA. 1994. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-1 (IGF-1)-mediated DNA synthesis and IGF-1 binding in a human breast carcinoma cell line. J Cell Physiol 158:69-78.
10. Chesik D, De Keyser J, Wilczak N. 2007. Insulin-like growth factor binding protein-2 as a regulator of IGF actions in CNS: Implications in multiple sclerosis. Cytokine Growth Factor Rev 18:267-278.
11. Courey AJ, Tjian R. 1988. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55:887-898.
12. Drop SLS, Schuller AGP, Lindenbergh-Kortleve DJ, Groffen C, Brinkman A, Zwarthoff EC 1992. Structural aspects of the IGFBP family. Growth Regul 2:69-79.
13. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W. 2007. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104:11736-11741. (Pubitemid 47175082)
14. DutcherJP, ColettiD, PaiettaE,WiernikPH. 1997.Apilot studyof alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 21:375-380.
15. Elminger MW, Bell M, Schuett BS, Langkamp M, Kutoh E, Ranke MB. 2001. Transactivation of the IGFBP-2 promoter in human tumor cell lines. Mol Cell Endocrinol 175:211-218.
16. Ernst CW, White ME. 1996. Hormonal regulation ofIGF-binding protein-2 expression in proliferating C2C12 myoblasts. JEndocrinol 149:417-429.
17. Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854.
18. Fottner C, Sattarova S, Hoffmann K, Spottl G, Weber MM. 2008. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: Correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin. EurJEndocrinol 159:317-327.
19. Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW. 2006. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 37:13-23.
20. Gingras AC, Raught B, Sonenberg N. 2004. mTOR signaling to translation. CurrTop Microbiol Immunol 279:169-197.
21. Han HJ, Kang CW, Park SH. 2006. Tissue-specific regulation of insulin-like growth factors and insulin-like growth factor binding proteins in male diabetic rats in vivo and in vitro. Clin Exp Pharmacol Physiol 33:1172-1179.
22. Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. 1999. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci USA 96:14866-14870.
23. Hoeflich A, Lahm H, Blum W, Kolb H, WolfE. 1998. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 434:329-334.
24. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, Wolf E, Weber MM. 2000. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 60:834-838.
25. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Olf E. 2001. Insulin-like growth factor-binding protein 2 in tumorigenesis: Protector or promoter? Cancer Res 61:8601-8610.
26. Hwa V, Oh Y, Rosenfeld RG. 1999. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787. (Pubitemid 30648894)
27. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
28. Kennedy BJ, Torkelson JL. 1995. Long-term follow-up ofstage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 24:327-328.
29. Lalou C, Lassarre C, Binoux M. 1996. Isolation and characteriz-ation of proteolytic fragments of insulin-like growth factor-binding protein-3. Horm Res 45:156-159.
30. Levitt RJ, Georgescu MM, Pollak M. 2005. PTEN-induction in U251 glioma cells decreases the expression ofinsulin-like growth factor binding protein-2. Biochem Biophys Res Commun 336: 1056-1061.
31. Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghow R, Solomon S. 2006. Insulin dynamically regulates calmodulin gene expression by sequential o-glycosyla-tion and phosphorylation of sp1 and its subcellular compart-mentalization in liver cells. J Biol Chem 281:3642-3650.
32. Martin JL, Baxter RC. 2007. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 148: 2532-2541.
33. Mayer C, Zhao J, Yuan X, Grummt I. 2004. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18:423-434.
34. McDonald KL, O'Sullivan MG, ParkinsonJF, ShawJM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, Biggs MT, Little NS, Teo C, Stone G, Robinson BG. 2007. IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66: 405-417.
35. Menouny M, Binoux M, Babajko S. 1998. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity. Int J Cancer 77:874-879.
36. Mohan S, Baylink DJ. 2002. IGF-binding proteins are multi-functional and act via IGF-dependent and-independent mechanisms. J Endocrinol 175:19-31.
37. Okabe E, Kajihara J, Usami Y, Hirano K. 1999. The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3. FEBS Lett 447:87-90.
38. Parker A, Rees C, Clarke J, Busby WH, Jr, Clemmons DR. 1998. Binding ofinsulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Mol Biol Cell 9:2383-2392.
39. Perks CM, Vernon EG, Rosendahl AH, Tonge D, HollyJM. 2007. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26:5966-5972.
40. Richardsen E, Ukkonen T, Bjornsen T, Mortensen E, Egevad L, Busch C. 2003. Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 442:329-335.
41. So A, Levitt RJ, Eigl B, Fazil L, Muramaki M, Leung S, Cheang M, Nielsen T, Gleave M, Pollak M. 2008. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14:6944-6954.
42. Solomon SS, Majumdar G, Martinez-Hernandez A, Raghow R. 2008. A critical role of Sp1 transcription factor in regulating gene expression in response to insulin and other hormones. Life Sci 83:305-312.
43. Sommer A, Spratt SK, Tatsuno GP, Tressel T, Lee R, Maack CA. 1993. Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 (IGFBP-3). Growth Regul 3:46-49.
44. Tan NY, Khachigian LM. 2009. Sp1 phosphorylation and its regulation ofgene transcription. Mol Cell Biol 29:2483-2488.
45. Yu J, Iwashita M, Kudo Y, Takeda Y 1998. Phosphorylated insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth Horm IGF Res 8:65-70.
46. ZumkellerW, SchwanderJ, Mitchell CD, Morrell DJ, Schofield PN, Preece MA. 1993. Insulin-like growth factor (IGF)-I,-II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumor. Eur J Cancer 29A:1973-1977.